Mike Bentivegna is currently Vice President, Commercial Development and Lifecycle Innovation a Zoetis Inc, the worlds largest Animal Health company. He leads a group of 20 colleagues responsible for, in collaboration with R&D and Commercial, establishing species innovation strategies that drive value in Zoetis’ R&D portfolio, aligning the broader organization to market and asset development strategies, and preparing new products for global launch. In the past five years Zoetis has launched multiple animal health blockbuster products including Apoquel, Cytopoint and Simparica. Mike is a thirty-one year veteran of Pfizer/Zoetis. He joined Animal Health in late 2010 as head of U.S. Companion Animal Marketing, where he served for five years, contributing to the business units success and elevating the skill set of its marketers. Zoetis was spun off from Pfizer in an IPO in 2013.
Mike previously spent thirteen years in Pfizer Human Health Marketing in senior marketing positions on major brands and therapeutic areas like Zyrtec, Zyvox, Spiriva, Eliquis, Pain and Inflammation (Celebrex), Cardiovascular (Lipitor/Caduet) in both U.S. Marketing and Global Commercial Development positions. Prior to human health, Mike spent his first ten years in Pfizer’s OTC division working on all of Pfizer’s leading OTC medicines and was the named the first global team leader for the division, responsible for the Eye Care TA and global strategy for the Visine franchise.
Mike is graduate of Fairfield University with a BS in Marketing and where he was elected Student Government President his senior year. He holds an MBA from the Sawyer School of Management at Suffolk University, where he received a full tuition graduate assistantship.
Mikes’ volunteer and support activities include Wakeman Boys and Girls Club, Operation Hope and Fairfield University where he was a past member of the Alumni Board of Directors and a mentor to Creative Life Sophomore Residential College students. He has been a member of the Fairfield President’s Circle for over twenty years and serves on the Deans Advisory Board of the Dolan School of Business
Mike lives in Southport, Connecticut with his wife Wendy and feline family members Ritz and Pippin. He has two adult children, Kevin and Brittney.
Alexander Brown has over 20 years’ experience developing and commercializing innovative medicines in oncology and infectious diseases. Mr. Brown is the Head of the New Products Oncology team at Sanofi-Genzyme where he is responsible for the commercial readiness of the oncology pipeline and external collaborations. Prior to Sanofi, Mr. Brown played an integral role in the commercialization of BAVENCIO developed by Merck KGaA and Pfizer. While at Merck KGaA he was responsible for commercial readiness of BAVENCIO, first as New Products Lead and later as Global Marketing Launch Lead for both Merkel Cell Carcinoma and Lung cancer. Mr. Brown’s early career includes both development and commercial leadership roles at Sanofi-Pasteur, Repligen, CombinatoRx and Ariad Pharmaceuticals working on clinical development and launch-readiness for various products including ICLUSIG, ALUNBRIG and JEVTANA. Mr. Brown holds a BS in Microbiology and Infectious Diseases from the University of Wisconsin-Madison as well as an MBA from Carnegie-Mellon.
s the Vice President of Commercial Strategy & Business Development at Zafgen, Erin is a senior member of the core management team with responsibility for New Product Planning, Portfolio Management, Corporate Strategy and Business Development. Zafgen is a clinical-stage biopharmaceutical company developing novel therapies for patients affected by a range of metabolic diseases.
Prior to joining Zafgen, Erin was an executive at GlaxoSmithKline where she held several VP roles in the Pharmaceuticals business and led global teams in Marketing, Business Development and R&D Strategy. Over her 25-year career in the Pharmaceutical Industry, Erin held several roles of increasing responsibility in Sales, Marketing, New Product Planning, Business Development and R&D, which allowed her to gain significant experience in the complex tradeoffs and decision-making that goes into the discovery, development and commercialization of new medicines.
Career highlights for Erin include: leading the Alliance Management team that was recognized globally in the BCG Survey; contributing to the in-licensing of several high value assets; successfully launching a new medicine in the US, where Erin was selected as one of the ‘Top Marketing 100’ by Advertising Age magazine; and being named a ‘Rising Star’ by the Healthcare Businesswomen’s Association. Erin is known for her high-energy, ability to build meaningful and lasting professional relationships, and her authentic leadership style. Erin was part of the team that initiated the Women’s Leadership Initiative at GlaxoSmithKline. She actively mentors both men and women in the Industry at all stages in their careers. Erin currently serves on the Board of Life Sciences PA and has previously served on Boards of other non-profit organizations focused on patient advocacy and finance.
Erin is a graduate of Franklin & Marshall College. She also completed the Transformational Executive Program associated with the Wharton Executive Education Program at the University of Pennsylvania. She holds a certification in coaching from the Association for Professional Executive Coaching & Supervision, and a Certificate of Achievement in Alliance Management from the Association of Strategic Alliance Professionals. Erin and her family live in the Greater Philadelphia area and are lifelong, admittedly sometimes suffering, supporters of the Philadelphia sports teams.
Eric serves as the Head of New Product Planning for Talaris Therapeutics. He joined from Radius Health, where he led commercial insights and analytics efforts for the company’s portfolio of medicines in the areas of osteoporosis, oncology, and endocrine diseases. While at Radius, he helped build the commercial operations organization and infrastructure to launch their first product, TYMLOS (TM) in the United States. Previously, Eric served in roles of increasing authority in market and business development at Biogen, Millennium, TransForm, Acceleron and AstraZeneca; led strategy engagements at Leerink Partners Consulting (acquired by Navigant Consulting’s Life Sciences practice); and authored global biopharmaceutical market studies at Decision Resources. He began his career conducting pediatric genetic research at Boston Children’s Hospital. Eric has a BA with distinction in biology from Boston University, where he was a Trustee Scholar, and an MBA from MIT Sloan School of Management.
Paul oversees our business activities in North America. Since completing his PhD in chemistry at Stony Brook University, he has spent more than 20 years providing guidance and support to the healthcare industry. He has held leadership roles at various consulting firms that engage with biopharmaceutical and medical technology companies in nearly all functional areas, including sales, marketing, medical affairs, business development and supply chain. Paul’s focus at Prescient is helping our clients achieve and sustain peak commercialization targets across a wide range of therapy areas.
Elaine Hughes is currently the Executive Director of Commercial Development for the Immunology & Inflammation (I&I) franchise at Celgene. She leads New Product Planning, Competitive Intelligence, and Business Development for I&I. In New Product Planning, she and her team provide commercial direction for all new products in the pipeline across Rheumatology, Dermatology, Neurology and Fibrosis. Elaine joined Celgene in 2015, leading Global Marketing for Rheumatology during the global launch of OTEZLA.
Prior to joining Celgene, she spent over 15 years at J&J, working on commercialized and development-stage brands in both U.S. and Global Marketing. In her role as Global Marketing Leader, she represented a portfolio of over 20 products in development from Discovery through Phase 3 across over 10 diseases. She also led Hospital Marketing for REMICADE, SIMPONI and STELARA in the U.S., representing nearly $2B in annual business.
Elaine began her career at Boehringer Mannheim (now Roche) in a variety of roles in market research and analytics, leading primary and secondary research, competitive intelligence, and forecasting. Elaine received her M.B.A. in Biotechnology and Healthcare from Penn State. She is an adjunct professor at Jefferson University, lecturing on the role of marketing in drug development.
Christine Leighland (pronounced LAY-LAND) is addicted to change and challenge.
She has lived and worked in 5 different countries including US, UK, Germany, Switzerland and Canada.
Her responsibilities have included sales, marketing, training, access, medical, and general management with companies such as Astra Zeneca, Takeda, Actelion, A.L.K., Shire, and Biogen.
She fundamentally believes that people are of utmost importance so she takes time to help others reach their full potential.
Christine chooses to work in New Product Planning because it is the best way to apply her experience and give back to individuals with unmet biopsychosocial needs.
Finally, Christine is redefining what it means to be 50: she won Rookie of the Year in Ultimate Frisbee, she’s learning how to play the drums, and is working on her second Master’s degree.
Most importantly, she has tamed her Workaholism and Perfectionism demons and is pleased to share that she puts her family first.
Dr. Arup Pramanik is currently Global Head Market Access & Strategic Planning for Indivior, a Neuro Science based company . Prior to which he was VP, Value & Access at Shire Oncology, held Senior Global & Regional Leadership roles with Novartis Oncology and Pfizer . He is a Physician by training with the Royal College of Physicians, Ireland and a post graduate in Health Economics & Policy from London School of Economics.
For nearly two decades now, he led Medical Affairs, Market Access, Pricing , HEOR, New Product Planning, Marketing and Strategy Teams. He is recipient of multiple awards for access and innovative models with these organizations. Having launched a score and more, new products across the globe. Is passionate to learn from other and to share his learnings, so as to collectively improve access for patients globally while conscious of the complexity of successful bed to bench launch executions, within Health care systems, that reward innovation in very constrained and competing health financing environments.
Anne Marie is Vice President, ONYVIDYE ®at Ipsen Biopharmaceuticals. She has is long history of new product planning and product launches in Oncology. Anne Marie brings her passion for patients to her teams.
Anne Marie has experienced both the large pharma approach to product launch as well as the small biotech approach over her career. Before joining Ipsen, Anne Marie was responsible for the Akynzeo launch and launch planning for anamorelin at Helsinn Therapeutics. Anne Marie was the Group Leader for Pfizer’s Renal Cell Carcinoma products: Sutent, Torisel, and Inlyta, and designed a franchise approach to the promotion of all three products including the launch of Inlyta and a new indication for Sutent. Anne Marie had a variety of roles before joining Pfizer: Vice President, New Product Marketing at ImClone Systems, Vice President, Global Marketing at GPC Biotech and Global Brand Champion for Tarceva at OSI Pharmaceuticals where she supported the new indication in Pancreatic Cancer, and Early Brand Team Lead for the VEGF-Trap at Aventis. Anne Marie started her career in Oncology at Bristol-Myers Squibb in a variety of sales and marketing roles of increasing responsibility including Field Sales in New York, District Management in Texas, and Marketing Director for the launch of Erbitux.
Anne Marie volunteers for Cancer Care of NJ and Cranford High School Project Graduation. She earned her B.S. in Biology from Rensselear Polytechnic Institute and her M.B A. in Marketing from Baruch College.
Tony Russell is currently the Executive Director, Product Strategy and Commercial Planning on Theravance Biopharma US, Inc. with a primary focus on new product planning for respiratory and rare diseases. Tony’s prior therapeutic area experiences include dermatology, pain, oncology, rare diseases, anemia, and nephrology.
Over the course of Tony’s nearly 20-year career, he has established a unique blend of skills and therapeutic area knowledge providing valuable perspectives and insights for the development and commercialization of biologic and small molecule therapeutics. Tony has successfully utilized these experiences in developing commercialization strategies and evaluations for new drug candidates as well as in the market conditioning and launching of new therapeutics.
Réka Shinkle joined REGENXBIO as the Vice President, Commercial and Portfolio Planning in 2015. Previously, Ms. Shinkle held increasing commercial responsibility spanning small molecule and biologic products in multiple therapeutic areas at Lilly, MedImmune, and AstraZeneca. Ms. Shinkle’s current responsibilities include building the commercial function at REGENXBIO while ensuring development of insight-driven gene therapy
Debasish is a Vice President and leads our Advisory business. He started his career as a licensed medical practitioner and holds an MBA from the Indian Institute of Management Calcutta. After a brief stint at P&G, he made the move to strategy consulting, and then spent ten years at Bain & Company, where he was a leader in the healthcare practice. Debasish has extensive international experience advising biopharma clients on value creation through corporate, business unit, disease area and product-focused strategies.
Katja Wachtendonk is a Senior Director, Global New Product Planning at Novartis Pharma. In her role, Katja is responsible to establish Novartis Global Cardio-renal & Metabolic Disease Area- and Program Strategies for compounds in Ph-I to early Ph-III in close collaboration with R&D. Katja leads and aligns portfolio strategies to maximize the value of assets and execute against short- and long-range franchise goals, provides commercial expertise to support BD&L, identifies transformational strategies (biomarker, diagnostics, etc) and innovates by leveraging technology-enabled solutions to improve patient outcomes.
Prior to that role, Katja spent more than a decade in global and local marketing leadership roles on Merck and Novartis blockbuster products SINGULAIR, COZAAR, ULTIBRO, QVM149, QAW039 from early Ph-III through launch and LoE in the U.S., Germany and Japan, and supported the companies’ business in Europe, AMAC and LACAN.
Katja holds a Pharm.D. from the Freie Universitaet Berlin (Germany).